{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:02:38Z","timestamp":1793037758197,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":1801,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1093\/annonc\/mdu544","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T04:39:16Z","timestamp":1416285556000},"page":"313-320","source":"Crossref","is-referenced-by-count":269,"title":["Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12"],"prefix":"10.1016","volume":"26","author":[{"given":"M.","family":"Gnant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Mlineritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Stoeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Luschin-Ebengreuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Knauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jakesz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Taucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bjelic-Radisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Balic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Eidtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Eiermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Steger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Kwasny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Dubsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fitzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hochreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Wette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sevelda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ploner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fesl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu544_bb0010","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000351193","article-title":"St. Gallen 2013: brief preliminary summary of the consensus discussion","volume":"8","author":"Harbeck","year":"2013","journal-title":"Breast Care (Basel)"},{"key":"10.1093\/annonc\/mdu544_bb0015","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu544_bb0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.2009.05349.x","article-title":"Bone turnover across the menopause transition: the role of gonadal inhibins","volume":"1192","author":"Nicks","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1093\/annonc\/mdu544_bb0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdu544_bb0030","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0035","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdu544_bb0040","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0045","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdu544_bb0050","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","article-title":"Exploring the anti-tumour activity of bisphosphonates in early breast cancer","volume":"34","author":"Winter","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdu544_bb0060","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu544_bb0065","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0070","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0075","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0080","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu544_bb0085","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","article-title":"Oral bisphosphonate use and breast cancer incidence in postmenopausal women","volume":"28","author":"Chlebowski","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0090","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/sj.bjc.6605555","article-title":"Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk","volume":"102","author":"Newcomb","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdu544_bb0095","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1200\/JCO.2010.28.1113","article-title":"Use of bisphosphonates and risk of postmenopausal breast cancer","volume":"28","author":"Rennert","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0100","first-page":"1807","article-title":"Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer","volume":"30","author":"Rack","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdu544_bb0105","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1158\/1078-0432.CCR-07-0247","article-title":"Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid","volume":"13","author":"Brown","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdu544_bb0110","series-title":"Presented at the ASCO 47th Annual Meeting, 3\u20137 June, Chicago, IL","article-title":"Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: long-term results from ABCSG-12","author":"Gnant","year":"2011"},{"key":"10.1093\/annonc\/mdu544_bb0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ctrv.2011.09.003","article-title":"Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature","volume":"38","author":"Gnant","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdu544_bb0120","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cell.2009.11.025","article-title":"Tumor self-seeding by circulating cancer cells","volume":"139","author":"Kim","year":"2009","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdu544_bb0125","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/jnci\/djs263","article-title":"Effects of bone-targeted agents on cancer progression and mortality","volume":"104","author":"Coleman","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu544_bb0130","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0135","series-title":"Presented at the 36th Annual San Antonio Breast Cancer Symposium, 10\u201314 December, San Antonio, TX","article-title":"Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomised trials","author":"Coleman","year":"2013"},{"key":"10.1093\/annonc\/mdu544_bb0140","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2012.47.2167","article-title":"German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0145","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/02841860801964988","article-title":"Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer","volume":"47","author":"Kristensen","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdu544_bb0150","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.2174\/1381612820666140826153711","article-title":"Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance","volume":"20","author":"Kesmodel","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1093\/annonc\/mdu544_bb0155","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu544_bb0160","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","article-title":"Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial","volume":"29","author":"Pfeiler","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419313912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419313912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/2\/313\/16697980\/mdu544.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:46:15Z","timestamp":1624520775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419313912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0923753419313912"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu544","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}